Peringkat dalam Saham
#8990
Inventiva S.A. is a biopharmaceutical firm currently in the clinical... Inventiva S.A. is a biopharmaceutical firm currently in the clinical development phase, specializing in creating orally administered small molecule treatments for conditions such as non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and various other ailments. Their primary drug candidate, Lanifibranor, has successfully concluded Phase IIb clinical trials for the management of NASH. Furthermore, the company is advancing Odiparcil, a compound that has finished Phase IIa clinical testing specifically for treating the MPS VI subtype. Beyond these, Inventiva maintains a development pipeline featuring several early-stage projects targeting oncology and other medical conditions. Strategic partnerships are in place with AbbVie to address autoimmune diseases, and with Boehringer Ingelheim International GmbH for innovating therapies for idiopathic pulmonary fibrosis. Established in 2011, Inventiva S.A. operates from its headquarters in Daix, France.
Harga Saham
$4.74
Terakhir disinkronkan: 2026-08-28
Kapitalisasi Pasar
$1.12B
Perubahan (1 hari)
-5.77%
Perubahan (1 tahun)
-16.96%
Perdagangan Inventiva S.A. (IVA)
Harga IVA dengan kapitalisasi pasar B
Kapitalisasi pasar dari Inventiva S.A.(IVA)
Kapitalisasi Pasar: $1.12B
Per August 2026, Inventiva S.A. memiliki kapitalisasi pasar sebesar $1.12B. Ini menjadikan Inventiva S.A. sebagai perusahaan 8990th paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar Inventiva S.A. dari 2017 hingga 2026
IVA dibandingkan dengan 5 teratas stocks paling populer
| Harga IVA |
|
Aset B |
Pasar B |
Hasil |
|
|
|
|
$5.264T
|
+469,562.19%
|
|
|
|
|
$4.701T
|
+419,365.62%
|
|
|
|
|
$4.177T
|
+372,603.60%
|
|
|
|
|
$3.817T
|
+340,502.96%
|
|
|
|
|
$2.866T
|
+255,645.41%
|
